Myeloma XI ’s Phase III trial result shows increase in myeloma patient remission

Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news